托珠单抗治疗COVID-19肺炎的疗效:CT纹理分析在定量评估治疗反应中的作用
本研究回顾性比较了接受托珠单抗治疗的30例COVID-19患者与仅接受抗病毒/抗疟药的27例对照组,通过半定量评分和纹理分析评估CT及实验室指标变化。结果显示托珠单抗组治疗后CT纹理特征显著改变而CT评分无显著差异,氧合指数改善且炎症标志物下降,重症病例减少,提示CT纹理分析可能有助于评估治疗反应。
要点
- 托珠单抗组治疗后CT半定量评分无显著变化,但纹理特征(平均衰减值、偏度、熵等)显著改变,提示肺实质病变消退。
- 对照组随访时CT评分、纹理特征及实验室指标均显著恶化,重症病例从6/27增至14/27。
- 托珠单抗组PaO2/FiO2从240±93升至363±107(p=0.0003),炎症标志物(CRP、D-二聚体、LDH)平行下降。
核心结论
- CT纹理分析可能有助于评估COVID-19肺炎对托珠单抗的治疗反应,较半定量评估更能反映肺实质内在变化。
研究设计与样本
- 回顾性研究,纳入2020年3月11日至4月20日57例SARS-CoV-2阳性患者,托珠单抗组30例,对照组27例,分析治疗前后胸部CT及实验室指标,采用半定量评分和纹理分析,生存和出院分析采用Kaplan-Meier法。
关键影像表现/征象
- 托珠单抗组治疗后CT纹理特征显著改变,包括平均衰减值(p<0.0001)、偏度(p<0.0001)、熵(p=0.0146)及高阶参数,提示肺实质病变明显消退。
- 对照组随访时CT评分、纹理特征及实验室参数均显著恶化。
- 托珠单抗组重症病例从21/30降至5/30(p<0.0001),对照组重症病例从6/27增至14/27(p=0.0473)。
临床应用与阅片要点
- 在评估COVID-19肺炎治疗反应时,除半定量CT评分外,可关注纹理特征(平均衰减值、偏度、熵等)的变化,其可能更敏感地反映肺实质病变的消退。
- 托珠单抗组治疗后PaO2/FiO2从240±93升至363±107(p=0.0003),炎症标志物(CRP、D-二聚体、LDH)平行下降,可与影像变化结合解读。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate CT and laboratory changes in COVID-19 patients treated with tocilizumab, compared to a control group, throughout a combined semiquantitative and texture analysis of images.
MATERIALS AND METHODS: From March 11 to April 20, 2020, 57 SARS-CoV-2 positive patients were retrospectively compared: group T (n = 30) receiving tocilizumab and group non-T (n = 27) undergoing only antivirals/antimalarials. Chest-CT and laboratory findings were analyzed before and after treatment. CT evaluation included both semiquantitative scoring and texture analysis of all parenchymal lesions. Survival and recovery analyses were also provided with Kaplan-Meier method.
RESULTS: In group T, no significant differences were found for CT score after treatment, while several texture features significantly changed, including mean attenuation (p < 0.0001), skewness (p < 0.0001), entropy (p = 0.0146) and higher-order parameters, suggesting considerable fading of parenchymal lesions. PaO2/FiO2 mean value significantly increased after treatment, from 240 ± 93 to 363 ± 107 (p = 0.0003), with parallel decrease in inflammatory biomarkers (CRP, D-dimer and LDH). In group non-T, CT scoring, texture and laboratory parameters showed significant worsening at follow-up. Findings were clinically associated with opposite trends between two groups, with reduction of severe cases in group T (from 21/30 to 5/30; p < 0.0001) as compared to a significant worsening in group non-T (severe cases increasing from 6/27 to 14/27; p = 0.0473). Probability of discharge was significantly higher in group T (p < 0.0001), as well as survival rate, although not statistically significant.
CONCLUSIONS: Our results suggest the potential role of CT texture analysis for assessing response to treatment in COVID-19 pneumonia, using Tocilizumab, as compared to semiquantitative evaluation, providing insight into the intrinsic parenchymal changes.
引用
- Masci GM, Iafrate F, Ciccarelli F, et al. Tocilizumab effects in COVID-19 pneumonia: role of CT texture analysis in quantitative assessment of response to therapy. Radiol Med. 2021. PMID: 34089436. doi:10.1007/s11547-021-01371-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。